Dolutegravir--a promising antiretroviral in development
- PMID: 22018759
- DOI: 10.1016/S1473-3099(11)70291-2
Dolutegravir--a promising antiretroviral in development
Comment on
-
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.Lancet Infect Dis. 2012 Feb;12(2):111-8. doi: 10.1016/S1473-3099(11)70290-0. Epub 2011 Oct 20. Lancet Infect Dis. 2012. PMID: 22018760 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
